Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome

Journal of Endocrinological Investigation

Volumn 34, Issue 6, 2011, Pages 422-426

  Rizzo, M ^a   Longo, R A ^a   Guastella, E ^a   Rini, G B ^a   Carmina, E ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cardiovascular risk; Lipids; Metabolic syndrome; Polycystic ovary syndrome

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANOVULATION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; OVULATION; PREVALENCE; SOUTHERN EUROPE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; MALE; METABOLIC SYNDROME X; POLYCYSTIC OVARY SYNDROME; PROGNOSIS; RISK FACTORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 79953111306     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/7294     Document Type: Article

References (30)

1. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentration and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985, 61: 946-51.
2. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000, 132: 989-93.
3. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001, 111: 607-13.
4. Guzick DS. Cardiovascular risk in PCOS. J Clin Endocrinol Metab 2004, 89: 3694-5.
5. Rizzo M, Berneis K, Spinas GA, Rini GB, Carmina E. Long-term consequences of polycystic ovary syndrome on cardiovascular risk. Fertil Steril 2009, 91: 1563-7.
6. Essah PA, Nestler JE, Carmina E. Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome. J Endocrinol Invest 2008, 31: 35-41.
7. Berneis K, Rizzo M, Lazzarini V, Fruzzetti F, Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2007, 92: 186-9.
8. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81: 19-25.
9. Apridonidze T, Essah PA, Iuomo MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90: 1929-35.
10. Dokras A, Bochner M, Hollinrake E, Markhan S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005, 106: 131-7.
11. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol 2006, 154: 141-5.
12. Vrbikova J, Vondra K, Cibula D, et al. Metabolic syndrome in young Czech women with polycystic ovary syndrome. Hum Reprod 2005, 20: 3328-32.
13. Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, Pasternak RC, Smith Jr SC, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004, 44: 720-32.
14. Rosenzweig JL, Ferrannini E, Grundy SM, et al; Endocrine Society. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93: 3671-89.
15. Xydakis AM, Ballantyne CM. Role of non-high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials. Curr Opin Cardiol 2003, 18: 503-9.
16. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining Polycystic Ovary Syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab2006, 91: 4237-45.
17. Carmina E. Prevalence of idiopathic hirsutism. Eur J Endocrinol 1998, 139: 421-3.
18. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006, 91: 2-6.
19. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003, 9: 505-14.
20. Carmina E, Orio F, Palomba S, Longo RA, Lombardi G, Lobo RA. Ovarian size and blood flow in women with polycystic ovary syndrome (PCOS) and their correlations with some endocrine parameters. Fertil Steril 2005, 84: 413-9.
21. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106: 3143-421.
22. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112: 2735-52.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972, 18: 499-502.
24. Barter P, Gotto AM, LaRosa JC, et al; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357: 1301-10.
25. Mudali S, Dobs AS, Ding J, Cauley JA, Szklo M, Golden SH; atherosclerosis risk in communities study. Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study. J Clin Endocrinol Metab 2005, 90: 1202-9.
26. Liu Y, Ding J, Bush TL, Longenecker JC, Nieto FJ, Golden SH, Szklo M. Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation. Am J Epidemiol 2001, 154: 489-94.
27. Shelley JM, Green A, Smith AM, Dudley E, Dennerstein L, Hopper J, Burger H. Relationship of endogenous sex hormones to lipids and blood pressure in mid-aged women. Ann Epidemiol 1998, 8: 39-45.
28. Iverius P, Brunzell JD. Relationship between lipoprotein lipase activity and plasma sex steroid levels in obese women. J Clin Invest 1988, 82: 1106-12.
29. Haffner SM, Newcomb PA, Marcus PM, Klein BE, Klein R. Relation of sex hormones and dehydroepiandrosterone sulfate (DHEA-S04) to cardiovascular risk factors in postmenopausal women. Am J Epidemiol 1995 142: 925-34.
30. Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinas GA, Carmina E. Milder forms of atherogenic dyslipidemia in ovulatory vs. anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009, 24: 2286-92.